Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson pROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2021
223
Period ended Jan 2, 2022
Change on a year earlier
-19.5%
277 in FY2020
History
6 years
Since FY2016
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Jan 2, 2022 | 223 | -19.5% | Form 10-K (filed 2022-02-17) ↗ |
| FY2020 | Jan 3, 2021 | 277 | -45.1% | Form 10-K (filed 2022-02-17) ↗ |
| FY2019 | Dec 29, 2019 | 505 | -25.1% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 674 | -0.1% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 675 | -12.0% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 767 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up procrit / eprex (epoetin alfa) [reported separately through fy2021q4] — u.s. sales ($m)
Cite this data
StockData. (2026). Johnson & Johnson PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — U.S. sales ($M) ($M), annual FY2016–FY2021 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_procrit_us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.